Capital International Sarl Increases Position in Pfizer Inc. (NYSE:PFE)

Capital International Sarl lifted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 3.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 356,477 shares of the biopharmaceutical company's stock after buying an additional 12,495 shares during the period. Capital International Sarl's holdings in Pfizer were worth $9,457,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in PFE. Passumpsic Savings Bank grew its position in Pfizer by 8.4% in the 3rd quarter. Passumpsic Savings Bank now owns 25,680 shares of the biopharmaceutical company's stock worth $743,000 after purchasing an additional 1,998 shares during the period. Virtu Financial LLC purchased a new position in shares of Pfizer during the 3rd quarter worth $1,499,000. Westside Investment Management Inc. raised its holdings in Pfizer by 7.7% in the 3rd quarter. Westside Investment Management Inc. now owns 14,008 shares of the biopharmaceutical company's stock worth $404,000 after purchasing an additional 1,004 shares during the period. Diamant Asset Management Inc. increased its position in Pfizer by 8.4% in the third quarter. Diamant Asset Management Inc. now owns 8,515 shares of the biopharmaceutical company's stock worth $246,000 after buying an additional 660 shares in the last quarter. Finally, Morse Asset Management Inc purchased a new position in Pfizer during the third quarter valued at approximately $2,649,000. Institutional investors own 68.36% of the company's stock.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the business's stock in a transaction on Thursday, February 13th. The stock was bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. 0.06% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on PFE shares. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Cantor Fitzgerald initiated coverage on shares of Pfizer in a research report on Tuesday. They set a "neutral" rating and a $24.00 price objective on the stock. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. The Goldman Sachs Group reissued a "neutral" rating and set a $25.00 price target (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Finally, Citigroup reissued a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, five have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $29.57.

Pfizer Stock Performance

NYSE:PFE traded up $0.44 during mid-day trading on Tuesday, hitting $22.48. The company's stock had a trading volume of 11,811,883 shares, compared to its average volume of 40,342,807. The stock has a market cap of $127.47 billion, a price-to-earnings ratio of 15.95, a PEG ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The business's fifty day moving average is $24.81 and its two-hundred day moving average is $26.11. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. During the same period in the previous year, the business earned $0.10 earnings per share. The business's revenue was up 24.7% compared to the same quarter last year. Analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.